|
Abstract
|
Research shows that hemodialysis patients are at increased risk of bone resorption and fractures due to renal failure and associated metabolic changes [10]. On the other hand, calcitonin can act as a protective factor by reducing the destructive activity of osteoclasts. However, it is not yet known whether the levels of this hormone are decreased or show specific variations associated with an increased risk of fracture in hemodialysis patients.
The importance and need for this research arise from the growing number of hemodialysis patients and the serious bone complications they experience. The identification of an effective biomarker such as calcitonin may help in the early detection and prevention of fractures. If this study establishes a significant relationship between calcitonin levels and fracture risk in hemodialysis patients, calcitonin can be used as a diagnostic and therapeutic tool.
|